10 August 2024 - Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and development. 

Governments fund push incentives like CARB-X and GARDP, and G7 countries are now designing pull incentives—financial rewards given to manufacturers post-market authorisation that are intended to encourage the creation and introduction of novel antimicrobials.

This paper examines Germany’s reforms and contributes to the on-going debate about the merits of its approach in light of research & development and access issues impacting the country, particularly in comparison to pull incentives such as revenue guarantees or subscriptions that delink revenue from sales volume.

Read Nature article